- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00345735
Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients (FT-017-IM)
Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients. A Randomised, Double-blind, Placebo-controlled, Cross-over Confirmatory Trial Testing Fentanyl and Placebo in Eight Breakthrough Pain Episodes
Primary Objective:
To demonstrate the efficacy of intranasal fentanyl in the treatment of breakthrough pain (BTP) in cancer patients.
Secondary Objective:
To explore the relationship between the response to the fentanyl dose and the stable background pain opioid dose.
Studieöversikt
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Roskilde, Danmark, 4000
- Nycomed
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Has the patient given informed consent according to local requirements before any trial-related activities? Trial-related activities are any procedures that would not have been performed during the routine management of the patient.
- Is the patient a cancer patient with breakthrough pain?
- Is the patient aged ≥ 18 years?
- Has the patient received, for at least the past month, either oral morphine, oxycodone, hydromorphone, or transdermal fentanyl for treatment of background pain?
- Is the current dose of the scheduled background pain opioid of the patient equivalent to 60-500 mg oral morphine/day or to 25-200 µg/hour transdermal fentanyl?
- Is the background pain generally stable and on average controlled to a mild level (defined as ≤ 4 on an 11-point numerical rating scale [NRS]) by the background pain opioid?
- Is the BTP(s) in general of such severe pain intensity that the patient judges he/she needs additional analgesics (apart from background pain medication) and does it normally last for more than 15 minutes?
- Does the patient, in general, while using a stable fixed-schedule opioid regimen have at least three BTP episodes per week but no more than four BTP episodes per day?
- Has the patient obtained at least partial relief of BTP(s) with his/her usual immediate-release strong opioid, i.e. oral morphine, oxycodone, hydromorphone or transmucosal fentanyl?
- Is the life expectancy of the patient at least 3 months?
- Is the patient able to use intranasal drugs?
- Does the patient use adequate contraceptive precautions (contraceptive pill, implant or injection, or intrauterine device) in the trial period?
- Does the patient have a negative pregnancy test?
- Was the background pain, during a minimum of five of the seven days, controlled to a mild level (defined as ≤ 4 on an 11-point NRS) by the background pain opioid?
- Did the patient have at least three BTP episodes during the seven days but no more than four BTP episodes per day?
- Was the BTP(s) of such severe pain intensity that the patient took additional analgesics (apart from the usual background pain opioid)?
Exclusion Criteria:
- Does the patient have a recent history of substance abuse?
- Is the patient pregnant or nursing during the trial period?
- Does the patient have neurological or psychiatric impairment that may compromise data collection?
- Does the patient have severe hepatic impairment? (Investigator's judgement according to local practice.)
Has the patient had any recent therapy, which could potentially alter pain or response to analgesics to a degree, where the need for background pain opioid will be:
- less than 60 mg morphine or morphine equivalents/day; or
- less than 25 µg/hour transdermal fentanyl or the number of BTP episodes will be less than three per week during the trial period?
- Has the patient had facial radiotherapy?
- Has the patient been treated with a monoamine oxidase (MAO) inhibitor within the last 14 days?
- Does the patient use methadone or buprenorphine?
- Does the patient have impaired respiratory function to an extent which may severely increase the risk of clinically relevant respiratory depression by BTP fentanyl treatment?
- Does the patient use drugs for intranasal administration?
- Does the patient have a nasopharyngeal probe?
- Is the patient known to be hypersensitive to fentanyl or to other opioids or any of their excipients?
- Does the patient have any head injury, primary brain tumour, or other pathological conditions which could significantly increase the risk of increased intracranial pressure or impaired consciousness?
- Is the patient concomitantly participating in any other trial with an investigational drug or device apart from cancer treatment and participation in NAF trial FT-016-IM within 30 days prior to inclusion in this trial?
- Does the patient have pathological conditions of the nasal cavity as contraindications to intranasal fentanyl?
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Dubbel
Vad mäter studien?
Primära resultatmått
Resultatmått |
---|
Pain intensity difference at 10 minutes (PID10) after administration
|
Sekundära resultatmått
Resultatmått |
---|
Sum of pain intensity differences over the 0-60 minute time interval (SPID0-60) and General Impression (GI) with 5 point verbal rating scale at 60 minutes
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Smärta
- Neurologiska manifestationer
- Genombrottssmärta
- Läkemedels fysiologiska effekter
- Depressiva medel i centrala nervsystemet
- Agenter från det perifera nervsystemet
- Analgetika
- Sensoriska systemagenter
- Bedövningsmedel, intravenöst
- Anestesimedel, general
- Bedövningsmedel
- Analgetika, Opioid
- Narkotika
- Adjuvans, anestesi
- Fentanyl
Andra studie-ID-nummer
- FT-017-IM
- 2005-002347-82
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Smärta
-
Korea University Anam HospitalKorea UniversityAvslutadSmärtmätning | Visual Analog Pain Scale
-
Alanya Alaaddin Keykubat UniversityAvslutadSterilisering, Tubal | Visual Analog Pain Scale
-
Turkish Ministry of Health, Kahramanmaras Provincial...RekryteringVisual Analog Pain ScaleKalkon
-
Ankara UniversityAvslutadSmärtmätning | Visual Analog Pain ScaleKalkon
-
East Carolina UniversityIndragen
-
University Hospital, GrenobleAvslutadDövhet | Visual Analog Pain ScaleFrankrike
-
Moens MaartenRekryteringMisslyckad Ryggkirurgi Syndrom | Persistent Spinal Pain Syndrome Typ 2Belgien
-
Moens MaartenVrije Universiteit BrusselRekryteringRyggmärgsstimulering | Persistent Spinal Pain Syndrome Typ 2Belgien
-
Örebro University, SwedenAvslutadPostoperativ smärtintensitet | Rescue Pain KravSverige
-
Wake Forest University Health SciencesRekryteringPhantom Limb Pain (PLP)Förenta staterna
Kliniska prövningar på Fentanyl
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)AvslutadPeer Review, ForskningFörenta staterna
-
Alexza Pharmaceuticals, Inc.Avslutad
-
University of Texas Southwestern Medical CenterAvslutadGraviditetFörenta staterna
-
Janssen Research & Development, LLCAvslutad
-
University of PatrasOkändDödfödda kejsarsnittGrekland
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)Avslutad
-
Johns Hopkins UniversityAvslutadIntrakraniell kirurgiFörenta staterna
-
Ente Ospedaliero Cantonale, BellinzonaHar inte rekryterat ännu
-
Janssen Korea, Ltd., KoreaAvslutadKronisk smärtaKorea, Republiken av